{"name":"Iterum Therapeutics","slug":"iterum","ticker":"ITRM","exchange":"NASDAQ","domain":"iterumtx.com","description":"Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.","hq":"Dublin, Ireland","founded":0,"employees":"9","ceo":"Corey Fishman","sector":"Anti-Infectives / Clinical-Stage Biotech","stockPrice":0.03,"stockChange":0,"stockChangePercent":0,"marketCap":"$2M","metrics":{"revenue":390000,"revenueGrowth":0,"grossMargin":29.7,"rdSpend":10458000,"netIncome":-24774000,"cash":24125000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"sulopenem patent cliff ($0.0B at risk)","drug":"sulopenem","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"sulopenem etzadroxil and probenecid","genericName":"sulopenem etzadroxil and probenecid","slug":"sulopenem-etzadroxil-and-probenecid","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Sulopenem Etzadroxil/Probenecid","genericName":"Sulopenem Etzadroxil/Probenecid","slug":"sulopenem-etzadroxil-probenecid","indication":"Complicated urinary tract infections (cUTIs), including pyelonephritis","status":"phase_3"}]}],"pipeline":[{"name":"sulopenem etzadroxil and probenecid","genericName":"sulopenem etzadroxil and probenecid","slug":"sulopenem-etzadroxil-and-probenecid","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sulopenem Etzadroxil/Probenecid","genericName":"Sulopenem Etzadroxil/Probenecid","slug":"sulopenem-etzadroxil-probenecid","phase":"phase_3","mechanism":"Sulopenem etzadroxil/probenecid is a combination antibiotic that works by inhibiting bacterial cell wall synthesis and reducing the reabsorption of the antibiotic in the kidneys.","indications":["Complicated urinary tract infections (cUTIs), including pyelonephritis"],"catalyst":""}],"recentEvents":[{"date":"2023-02-16","type":"regulatory","headline":"Iterum Therapeutics Announces FDA Approval of Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections","summary":"Iterum Therapeutics announced that the FDA has approved sulopenem for the treatment of uncomplicated urinary tract infections.","drugName":"sulopenem","sentiment":"positive"},{"date":"2022-11-14","type":"earnings","headline":"Iterum Therapeutics Reports Third Quarter 2022 Financial Results","summary":"Iterum Therapeutics reported its third quarter 2022 financial results, including revenue and net loss.","drugName":"","sentiment":"neutral"},{"date":"2022-08-01","type":"deal","headline":"Iterum Therapeutics Announces Collaboration with the Bill and Melinda Gates Foundation to Develop New Antibiotics","summary":"Iterum Therapeutics announced a collaboration with the Bill and Melinda Gates Foundation to develop new antibiotics.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPeGVEcUN3bFRfMTBMemI4MWFObW5adGlsWk96cHYyTWE3QWkzOXZuYTZmdlc1S1pzYkhVeGVNRVdDQlQzSm50TkJueVZmZmtNMnRtY2hqdFdNZEJOUjRuaWk0OFQyRTdZRUtjSHhWdUxpdE9yMUlJRTIzX3lfaHAyRWFqYWNhTTQ2RFFyZHdyYk0tRnFMVkZxd3g4cU5VMUtsRDNLWjMzVldDMFBCczI4aXI4MlZtWXplcDRNV3VGbzJYMlZZRFhqTTRnYnJDRlBxcGlvY1I1b3BBUFl1SHBIVEZYNkJ6ZTdl0gHuAUFVX3lxTE1MS2YtMFFnenowTFhDR0ZMQ2REdnQ1eU1CeWVfYmIzdS0zaWlDWDkzQ3g2cUZrVHZCRVNiNXV5UGpxU3RjSHNmMzctNnI5YlZLM1NQZVl0V0laTVFtc1djd0p1QWRLd1JXeDZrQzdrMzI1Tm5HYkk2aEZlZ2h5ZzBfMHJ4MVB2RmktSW83d0xTZ2Q4bUZHV09yN25QcGgwOWk2WmNzYktRb1lUeVpIQjRVYzJ3THIwbVM0ZURzXzBFVUtoc1VycFBLbU10eWRRYWNqc3RLMWE5NmFoQURyWkNHRjY5aUlKRWpnT2dEYnc?oc=5","date":"2026-04-01","type":"pipeline","source":"simplywall.st","summary":"Breakeven On The Horizon For Iterum Therapeutics plc (NASDAQ:ITRM) - simplywall.st","headline":"Breakeven On The Horizon For Iterum Therapeutics plc (NASDAQ:ITRM)","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTFBHR2czSnhZSmtIdjgybVR0c1FNTjJBWmF0b0twLVgzaUQ4cHpPaVliYUptcWNmSUEzQTJhR3ktZlR5T3lmSmNlRllueFZRdnNmNlNmUk40WFZ0dDAzWkHSAWNBVV95cUxQeVJHQ3p0WjAtWHdvbHdLMDdmNXo2aENmYjBzU2xNVTU5RDFFekxRQlhlV3FVM1NqNEdZWmduM0gyZkJPbkVLZXRtbnYyS0FTQWVua1h4b3ZlNUptMGZqYjFEVGM?oc=5","date":"2026-03-27","type":"pipeline","source":"Bitget","summary":"Iterum Therapeutics Plummets 70%: What’s Behind the Freefall in ITRM? - Bitget","headline":"Iterum Therapeutics Plummets 70%: What’s Behind the Freefall in ITRM?","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9mRHJqN0s1WERaTldhSHVjcWRVOHFGZzFuMEtoeGJEZzZjNDQwUWZ5ZHBnZ0xyekpHekx5V3dHbXRvVU1CTGIyRTRRSE5xTjRKVG1veXp5SlBlNTNQVzQ5SXJyNkN5aHVRRnV6R1FB?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Iterum Therapeutics Plc (ITRM) - Stock Titan","headline":"If You Invested $1,000 in Iterum Therapeutics Plc (ITRM)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPeEJZa1haSzIwQ1E0cERpNmFTYUJvTk1EN1VrZmVQQlFSZlRrNnQydzF5NXZ6UEVGNGg3eDRfOWFOeDU0OWVEYUltMzNFUkhFOWNObGtQU0tzTV9TWGp5WGozOUJrcWhIa1JHbE11WUdjc1FhZWxidkp1RVRvbDFZUE81a0U?oc=5","date":"2026-03-03","type":"pipeline","source":"TipRanks","summary":"Why Is Iterum Therapeutics Stock (ITRM) Down Today? - TipRanks","headline":"Why Is Iterum Therapeutics Stock (ITRM) Down Today?","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNMFZHQzBtWlNGSlNqZHBlNHJQWlhtZmhjMERFYUZueVcxTTdIODFIUVB5UTZaYzNCZTBuWUxqR3pXQXNsekhhbm1fVlJ1UDZJQlF4eUxEUG1nOXVoeEgtTVI2bVJVUWVnR19Iamd2QzFKTDItQ2l0ME9EeEZRaUp5X3VfajJuR0oteHAycWZESVhXbE41eFVqVmVDbWNFc2ZPNU5qMUJwMzIzRkxtTGthdU96RFBpbjdvaE0xalBlQW5MWGVFQkE?oc=5","date":"2025-11-14","type":"earnings","source":"Quiver Quantitative","summary":"Iterum Therapeutics Launches ORLYNVAH™ in the U.S., Extends Cash Runway into Q2 2026 | ITRM Stock News - Quiver Quantitative","headline":"Iterum Therapeutics Launches ORLYNVAH™ in the U.S., Extends Cash Runway into Q2 2026 | ITRM Stock News","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxONWUxQU9PXzdKVXJjTkVDYnVYcjZWeTl5RU5EMWZPS0NCR29ZN3FUcFZmLUczWEloVXB6eGtKWjd5S1B0c21OcnlXLVFlNEFrbm5kQVZlSmpkS1paNndzd0ZhN25jcjJOMnNDQjBuaXo0aURWdW5kNlFXcEowOUZoWXR2TEpzZDZNMERMNG9yZzU1cmpIRXc?oc=5","date":"2025-10-17","type":"pipeline","source":"Yahoo Finance","summary":"Analysts Expect Breakeven For Iterum Therapeutics plc (NASDAQ:ITRM) Before Long - Yahoo Finance","headline":"Analysts Expect Breakeven For Iterum Therapeutics plc (NASDAQ:ITRM) Before Long","sentiment":"neutral"},{"date":"2025-10-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"sulopenem","drugSlug":"sulopenem","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Merck & Co.","Gilead Sciences"],"therapeuticFocus":["Anti-Infectives"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":0,"period":"2021-12-31"},{"value":0,"period":"2020-12-31"},{"value":37000,"period":"2019-12-31"},{"value":37000,"period":"2019-03-31"},{"value":869000,"period":"2018-12-31"},{"value":254000,"period":"2018-09-30"}],"grossProfit":-254000,"grossProfitHistory":[{"period":"2024-12-31","value":-254000},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":0}],"rdSpend":10458000,"rdSpendHistory":[{"period":"2024-12-31","value":10458000},{"period":"2023-12-31","value":39992000},{"period":"2022-12-31","value":17617000},{"period":"2021-12-31","value":10712000}],"sgaSpend":7984000,"operatingIncome":-18696000,"operatingIncomeHistory":[{"period":"2024-12-31","value":-18696000},{"period":"2023-12-31","value":-47468000},{"period":"2022-12-31","value":-30383000},{"period":"2021-12-31","value":-24537000}],"netIncome":-24774000,"netIncomeHistory":[{"period":"2024-12-31","value":-24774000},{"period":"2023-12-31","value":-38371000},{"period":"2022-12-31","value":-44434000},{"period":"2021-12-31","value":-91564000}],"eps":-1.26,"epsHistory":[{"period":"2024-12-31","value":-1.26},{"period":"2023-12-31","value":-2.728945},{"period":"2022-12-31","value":-3.346646},{"period":"2021-12-31","value":-7.744304}],"cash":24125000,"cashHistory":[{"period":"2024-12-31","value":24125000},{"period":"2023-12-31","value":6071000},{"period":"2022-12-31","value":21092000},{"period":"2021-12-31","value":27446000}],"totalAssets":44595000,"totalLiabilities":48676000,"totalDebt":45534000,"equity":-4081000,"operatingCashflow":-26770000,"operatingCashflowHistory":[{"period":"2024-12-31","value":-26770000},{"period":"2023-12-31","value":-39330000},{"period":"2022-12-31","value":-18473000},{"period":"2021-12-31","value":-15842000}],"capex":-2000,"capexHistory":[{"period":"2024-12-31","value":-2000},{"period":"2023-12-31","value":-13000},{"period":"2022-12-31","value":-62000},{"period":"2021-12-31","value":-61000}],"freeCashflow":-26772000,"dividendsPaid":null,"buybacks":null,"employees":9,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":6491000,"ebit":-8406000,"ebitda":-8051000,"period":"2025-09-30","revenue":390000,"epsBasic":-0.2,"netIncome":-8979000,"rdExpense":1261000,"epsDiluted":-0.2,"grossProfit":370000,"operatingIncome":-7731000},{"sga":4184000,"ebit":-6134000,"ebitda":-5783000,"period":"2025-06-30","revenue":0,"epsBasic":-0.16,"netIncome":-6509000,"rdExpense":1000000,"epsDiluted":-0.16,"grossProfit":-345000,"operatingIncome":-5529000},{"sga":2777000,"ebit":-4297000,"ebitda":-3948000,"period":"2025-03-31","revenue":0,"epsBasic":-0.14,"netIncome":-4891000,"rdExpense":591000,"epsDiluted":-0.14,"grossProfit":-342000,"operatingIncome":-3710000},{"sga":2117000,"ebit":-5683000,"ebitda":-5422000,"period":"2024-12-31","revenue":0,"epsBasic":-0.25,"netIncome":-6582000,"rdExpense":1299000,"epsDiluted":-0.25,"grossProfit":null,"operatingIncome":-3670000},{"sga":1780000,"ebit":-5368000,"ebitda":-5360000,"period":"2024-09-30","revenue":0,"epsBasic":-0.3,"netIncome":-6094000,"rdExpense":3107000,"epsDiluted":-0.3,"grossProfit":0,"operatingIncome":-4887000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.03,"previousClose":0,"fiftyTwoWeekHigh":1.42,"fiftyTwoWeekLow":0.03,"fiftyTwoWeekRange":"","fiftyDayAverage":0.21,"twoHundredDayAverage":0.52,"beta":3.01,"enterpriseValue":25367106,"forwardPE":0,"priceToBook":0,"priceToSales":4.1,"enterpriseToRevenue":65.04,"enterpriseToEbitda":-1.31,"pegRatio":0,"ebitda":-19324000,"ebitdaMargin":0,"freeCashflow":-13851125,"operatingCashflow":-19514000,"totalDebt":33735000,"debtToEquity":0,"currentRatio":2.13,"returnOnAssets":-53.3,"returnOnEquity":0,"analystRating":"","recommendationKey":"hold","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.8,"institutionHeldPercent":6.3,"sharesOutstanding":53291578,"floatShares":52370128,"sharesShort":3065983,"shortRatio":2.36,"shortPercentOfFloat":5.8,"epsTrailing":-0.72,"epsForward":0,"revenuePerShare":0.01,"bookValue":-0.15,"officers":[{"age":60,"name":"Mr. Corey N. Fishman","title":"President, CEO & Director"},{"age":55,"name":"Ms. Judith M. Matthews","title":"Chief Financial Officer"},{"age":65,"name":"Dr. Michael W. Dunne M.D.","title":"Strategic Advisor & Director"},{"age":null,"name":"Mr. Tom  Loughman Ph.D.","title":"Senior Vice President of Technical Operations"},{"age":null,"name":"Kevin  Dalton","title":"Senior Director of Legal Affairs & Company Secretary"},{"age":null,"name":"Dr. Steven I. Aronin M.D.","title":"Senior VP & Head of Clinical Development"},{"age":55,"name":"Ms. Christine R. Coyne M.B.A.","title":"Chief Commercial Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.iterumtx.com","phone":"353 1 903 8354"}}